Abstract
Background Increased alcohol consumption often co-occurs with mental health problems; however, we do not currently fully understand whether this is due to confounding, shared biological mechanisms, or causal effects.
Design We analysed a polygenic risk score (PRS) composed of single nucleotide polymorphisms (SNPs) reliably associated with patterns of adult alcohol consumption to test: 1) if this PRS is associated with consumption during pregnancy and adolescence, 2) if child alcohol PRS is associated with mental health phenotypes, and 3) if maternal alcohol PRS is associated with offspring alcohol phenotypes and mental health. We used data from the Avon Longitudinal Study of Parents and Children (ALSPAC). Additional substance abuse behaviours and mental health/behavioural outcomes were also investigated at different life stages across both generations (alcohol phenotypes n =22; health phenotypes n = 91). The availability of data from early life on the same participants (pre-alcohol use around ages 7-10 years) provided a negative control, in contrast to that in ages of alcohol use (13-24 years).
Findings The adult alcohol PRS was associated with consumption phenotypes during pregnancy (strongest signal for alcohol frequency at 18 weeks’ gestation: p=1.01×10-5) but offspring alcohol PRS did not predict offspring alcohol consumption at age 13-24 years. We found evidence for an association of maternal PRS with own perinatal depression (p=0.02) and decreased offspring intellectual ability (p=0.016).
Conclusions An alcohol PRS derived from GWAS of alcohol use in the general population was shown to be associated with frequency and amount of alcohol consumed during pregnancy, and maternal depression at 32 weeks gestation. The associations between alcohol PRS with mother’s depression and offspring intellectual ability are consistent with previous studies, adding to the validity of using this alcohol PRS in future aetiological studies.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the UK Medical Research Council and the Wellcome Trust (Grant ref: 102215/2/13/2) and the University of Bristol provide which provide core support for ALSPAC. This work was performed in the UK Medical Research Council Integrative Epidemiology Unit, jointly funded by the University of Bristol and the UK MRC, in which MRM leads one of the programmes (MC_UU_00011/7). The MRC also funded KEEs PhD studentship. LZ was supported by a UK Medical Research Council fellowship (grant number G0902144). This research was also supported by the NIHR Bristol Biomedical Research Centre at University Hospitals Bristol NHS Foundation Trust and the University of Bristol. The views expressed in this publication are those of the authors and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health and Social Care. NJT is a Wellcome Trust Investigator (202802/Z/16/Z), is the PI of the Avon Longitudinal Study of Parents and Children (MRC & WT 102215/2/13/2), is supported by the University of Bristol NIHR Biomedical Research Centre (BRC-1215-20011), the MRC Integrative Epidemiology Unit and works within the CRUK Integrative Cancer Epidemiology Programme (C18281/A19169). LS and EH are funded by CAPICE (Childhood and Adolescence Psychopathology: unravelling the complex etiology by a large Interdisciplinary Collaboration in Europe) project, funded by the European Unions Horizon 2020 research and innovation programme, Marie Sklodowska Curie Actions MSCA-ITN-2016 Innovative Training Networks under grant agreement number 721567. The UK Medical Research Council also funded the most recent collection of alcohol information in the ALSPAC participants (grant number MR/L033306/1. A comprehensive list of grants funding is available on the ALSPAC website (http://www.bristol.ac.uk/alspac/external/documents/grant-acknowledgements.pdf). GWAS data was generated by Sample Logistics and Genotyping Facilities at Wellcome Sanger Institute and LabCorp (Laboratory Corporation of America) using support from 23andMe. This publication is the work of the authors and they will serve as guarantors for the contents of this paper.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics approval for the study was obtained from the ALSPAC Ethics and Law Committee and the Local Research Ethics Committees.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data is available through application to the research executive of ALPSAC. Please note that the study website contains details of all the data that is available through a fully searchable data dictionary and variable search tool: http://www.bristol.ac.uk/alspac/researchers/our-data/.